Score Breakdown
Below average.
Amylyx is a binary bet on the Phase 3 LUCIDITY trial readout for avexitide in Q3 2026. The company has zero revenue, a $751M accumulated deficit, 60% annual dilution, an ongoing securities fraud class action, net insider selling, 25% short interest, and a management team whose credibility was severely damaged by the RELYVRIO debacle. The $317M cash position provides runway but is being steadily consumed at ~$30M/quarter. Even in a success scenario, the PBH market (160K patients, orphan indication, daily injectable) faces real-world adoption challenges including patient compliance and payer pushback. The current $1.36B market cap implies substantial probability of trial success and commercial execution that is not supported by the base rate of Phase 3 clinical trials (~50-60% success) or this management team's track record. At ~4x cash, the market is pricing in significant option value that may not be warranted given the risks. A failed trial would likely send shares to $3-4 (net cash per share after continued burn), representing 75%+ downside, while success might yield $25-30, creating an asymmetric but unfavorable risk-adjusted profile at current prices.
Negative cash flow. Can't value it.
Major red flags in SEC filings.
Shares melting fast.
Execs cashing out.
Tight but ok.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The core bear case centers on the company's 'all-or-nothing' dependency on a single pivotal event: the Phase 3 LUCIDITY trial data for avexitide (Post-Bariatric Hypoglycemia), expected in Q3 2026. Given the historical failure and withdrawal of Relyvrio in 2024, there is significant skepticism regarding Amylyx's ability to successfully navigate the regulatory and commercial landscape. Additionally, the company currently has no commercial revenue, a high cash burn, and a high valuation (P/B ratio of 7.13) that leaves zero margin for clinical error (Simply Wall St, Public.com).
🔍 What's In The SEC Filings
The company has transitioned into a speculative clinical-stage entity with zero revenue, a 60% annual dilution rate, and significant litigation overhang from its failed commercial asset.
Shareholder equity was aggressively diluted by 60% in one fiscal year to fund operations after product failure.
“On January 13, 2025, the Company closed an underwritten public offering of 19,714,285 shares... On September 10, 2025, the Company closed an underwritten public offering of 20,125,000 shares.”
Total shares outstanding jumped from 68.6 million to 109.9 million shares, as the company conducted two massive secondary offerings to raise $256 million in net proceeds to avoid insolvency.
The company has zero current revenue and has abandoned its only commercial product.
“In 2024, the Company voluntarily discontinued the marketing authorizations for RELYVRIO and ALBRIOZA... As a result, the Company does not expect to generate revenue from the sale of RELYVRIO and ALBRIOZA in future periods.”
The primary asset failed its Phase 3 trial endpoints, forcing a total market withdrawal and leaving the company with a $751.4 million accumulated deficit and no internal cash-generating capacity.
Class action litigation survived a motion to dismiss and is moving to confidential mediation.
“On September 30, 2025, the Court issued an order finding that the majority of the alleged misstatements are inactionable, but ultimately denied the motion to dismiss.”
The Shih Complaint alleges that management made materially false and misleading statements regarding the commercial prospects of RELYVRIO; the legal survival of these claims suggests a non-zero probability of a material settlement or judgment.
Massive inventory and software write-offs indicate complete loss of historical commercial value.
“Includes inventory impairment and loss on firm purchase commitments of zero and $118.7 million during years ended December 31, 2025 and 2024, respectively.”
The 2024 financials were devastated by $118.7M in inventory losses and $22.8M in restructuring costs as the company terminated 70% of its workforce to reset as a clinical-stage firm.
Intrinsic value is largely capped by the net cash position minus potential legal settlement reserves. The zero-revenue status requires a high-risk discount to all future cash flows from the unproven clinical pipeline.
Co-CEOs adopted 'non-Rule 10b5-1' trading arrangements in late 2025 to sell 400,000 total shares, which may signal lack of confidence in immediate pipeline catalysts. Management's strategic pivot relies entirely on unproven assets like Avexitide.